Reitz Capital Advisors’s AbbVie ABBV Stock Holding History

Reitz Capital Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-854	Closed	-$126K	–	25
2023 Q3	$126K	Buy	+854	New	+$125K	0.24%	27
2023 Q2	–	Sell	-1,411	Closed	-$225K	–	48
2023 Q1	$225K	Sell	1,411 -135	-9%	-$20.6K	0.21%	45
2022 Q4	$250K	Sell	1,546 -100	-6%	-$15.3K	0.24%	43
2022 Q3	$221K	Sell	1,646 -88	-5%	-$12.6K	0.2%	44
2022 Q2	$266K	Sell	1,734 -1,122	-39%	-$171K	0.24%	42
2022 Q1	$463K	Sell	2,856 -213	-7%	-$30.9K	0.34%	32
2021 Q4	$346K	Sell	3,069 -250	-8%	-$29.5K	0.24%	34
2021 Q3	$358K	Buy	3,319 +250	+8%	+$28.6K	0.27%	30
2021 Q2	$346K	Sell	3,069 -150	-5%	-$16.9K	0.24%	34
2021 Q1	$348K	Buy	3,219 +985	+44%	+$105K	0.26%	35
2020 Q4	$239K	Buy	+2,234	New	+$215K	0.19%	46
2020 Q3	–	Sell	-1,582	Closed	-$156K	–	49
2020 Q2	$156K	Buy	+1,582	New	+$139K	0.2%	37

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Reitz Capital Advisors's ABBV Position: Q4 2023 in Review

Reitz Capital Advisors sold out of AbbVie (ABBV) in Q4 2023, closing a stake of 854 shares — an estimated $126K sold.

Reitz Capital Advisors first reported a position in ABBV in Q2 2020 and held it in 12 quarters. The position peaked at $463K in Q1 2022. 3,327 funds tracked by Wall St. Rank hold ABBV as of Q4 2023.

Reitz Capital Advisors reported no remaining AbbVie position as of Q4 2023 after selling out during the quarter.
Reitz Capital Advisors sold 854 AbbVie shares in Q4 2023, an estimated $126K.
Reitz Capital Advisors first reported a position in AbbVie in Q2 2020 and held it in 12 quarters.
Reitz Capital Advisors's AbbVie position peaked at $463K in Q1 2022.
3,327 funds tracked by Wall St. Rank held AbbVie as of Q4 2023.

Based on Reitz Capital Advisors's 13F filing for Q4 2023, filed 17 Jan 2024.